| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1019919444 |
| P356 | DOI | 10.1186/1471-2172-10-43 |
| P8608 | Fatcat ID | release_eivwikygszd6njuei3duomdgvu |
| P932 | PMC publication ID | 2731061 |
| P698 | PubMed publication ID | 19650904 |
| P5875 | ResearchGate publication ID | 26713246 |
| P50 | author | Richard S Kornbluth | Q78503103 |
| Klaus Überla | Q89297358 | ||
| Matthias Tenbusch | Q89297763 | ||
| P2093 | author name string | Ghulam Nabi | |
| Godwin Nchinda | |||
| Geoffrey W Stone | |||
| Vladimir Temchura | |||
| Claudius Grossmann | |||
| P2860 | cites work | The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-beta promoter | Q24558779 |
| Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines. | Q27472925 | ||
| Taking dendritic cells into medicine | Q29619243 | ||
| T-cell quality in memory and protection: implications for vaccine design | Q30014840 | ||
| Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo | Q30080006 | ||
| Coexpression of GM-CSF and antigen in DNA prime-adenoviral vector boost immunization enhances polyfunctional CD8+ T cell responses, whereas expression of GM-CSF antigen fusion protein induces autoimmunity | Q33327757 | ||
| T cell vaccines for microbial infections | Q36090185 | ||
| Intensified and protective CD4+ T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccine | Q36228405 | ||
| The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments | Q36342606 | ||
| Rational design of gene-based vaccines | Q36346123 | ||
| Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance | Q36376611 | ||
| In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination | Q36402359 | ||
| An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses | Q36446900 | ||
| The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells | Q36489528 | ||
| The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine | Q36497412 | ||
| Antiviral signaling through pattern recognition receptors | Q36693188 | ||
| Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists | Q36811131 | ||
| Toll-like receptor ligands synergize through distinct dendritic cell pathways to induce T cell responses: implications for vaccines | Q36945037 | ||
| Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells | Q37139993 | ||
| A novel cardiotropic murine adenovirus representing a distinct species of mastadenoviruses | Q37191886 | ||
| Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. | Q37418499 | ||
| Paired Toll-like receptor agonists enhance vaccine therapy through induction of interleukin-12. | Q37612522 | ||
| Recruitment of antigen-presenting cells to the site of inoculation and augmentation of human immunodeficiency virus type 1 DNA vaccine immunogenicity by in vivo electroporation | Q38610641 | ||
| Production of lentiviral vectors by transient expression of minimal packaging genes from recombinant adenoviruses | Q40508727 | ||
| Immunological unresponsiveness characterized by increased expression of CD5 on peripheral T cells induced by dendritic cells in vivo | Q40547093 | ||
| Atraumatic oral spray immunization with replication-deficient viral vector vaccines | Q42910680 | ||
| EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone | Q46576663 | ||
| Induction of CD4+/CD25+ regulatory T cells by targeting of antigens to immature dendritic cells | Q56903879 | ||
| Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation | Q79213173 | ||
| Inducing and expanding regulatory T cell populations by foreign antigen | Q81392563 | ||
| Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers | Q82044309 | ||
| P921 | main subject | toll-like receptor | Q408004 |
| dendritic cell | Q506253 | ||
| P304 | page(s) | 43 | |
| P577 | publication date | 2009-08-03 | |
| P1433 | published in | BMC Immunology | Q2877163 |
| P1476 | title | Enhancement of the priming efficacy of DNA vaccines encoding dendritic cell-targeted antigens by synergistic toll-like receptor ligands | |
| P478 | volume | 10 |
| Q84074937 | Activation of antigen-specific T cell-responses by mannan-decorated PLGA nanoparticles |
| Q38226580 | Adaptation in the innate immune system and heterologous innate immunity |
| Q47572384 | CD205 antigen targeting combined with dendritic cell recruitment factors and antigen-linked CD40L activation primes and expands significant antigen-specific antibody and CD4(+) T cell responses following DNA vaccination of outbred animals. |
| Q37821483 | Combination adjuvants: the next generation of adjuvants? |
| Q38124060 | Combination of adjuvants: the future of vaccine design |
| Q37772265 | Control of important helminthic infections vaccine development as part of the solution |
| Q84335650 | Cysteine proteases as potential antigens in antiparasitic DNA vaccines |
| Q47143691 | Distinct Effects of Monophosphoryl Lipid A, Oligodeoxynucleotide CpG, and Combination Adjuvants on Modulating Innate and Adaptive Immune Responses to Influenza Vaccination |
| Q39738474 | Enhancing DNA immunization by targeting ASFV antigens to SLA-II bearing cells |
| Q36470265 | Formulation and delivery of vaccines: Ongoing challenges for animal management |
| Q64252010 | Glycosylation of HIV Env Impacts IgG Subtype Responses to Vaccination |
| Q37666077 | Gold nanoparticle mediated cancer immunotherapy |
| Q28728563 | Immunogenicity of DNA vaccines encoding simian immunodeficiency virus antigen targeted to dendritic cells in rhesus macaques |
| Q37919894 | Intradermal naked plasmid DNA immunization: mechanisms of action |
| Q34060493 | Memories that last forever: strategies for optimizing vaccine T-cell memory |
| Q34741882 | Newcastle disease virus expressing a dendritic cell-targeted HIV gag protein induces a potent gag-specific immune response in mice |
| Q42216302 | Optimization of the immunogenicity of a DNA vaccine encoding a bacterial outer membrane lipoprotein |
| Q41087956 | Priming with two DNA vaccines expressing hepatitis C virus NS3 protein targeting dendritic cells elicits superior heterologous protective potential in mice |
| Q37989884 | Prophylactic and therapeutic implications of toll-like receptor ligands |
| Q34943809 | Targeting DNA vaccines to myeloid cells using a small peptide |
| Q38162446 | Targeting antigens to dendritic cell receptors for vaccine development |
| Q40254340 | Targeting of envelope domain III protein of DENV type 2 to DEC-205 receptor elicits neutralizing antibodies in mice |
| Q44406147 | Targeting the antigen encoded by adenoviral vectors to the DEC205 receptor modulates the cellular and humoral immune response |
| Q91999288 | The STING activator c-di-AMP exerts superior adjuvant properties than the formulation poly(I:C)/CpG after subcutaneous vaccination with soluble protein antigen or DEC-205-mediated antigen targeting to dendritic cells |
| Q37724053 | Toll-like receptor 9 agonist enhances anti-tumor immunity and inhibits tumor-associated immunosuppressive cells numbers in a mouse cervical cancer model following recombinant lipoprotein therapy |
| Q37909430 | Using monoclonal antibodies to stimulate antitumor cellular immunity |
Search more.